Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups

DOI10.1002/sim.9120zbMath1546.62436MaRDI QIDQ6628021

Pavlos Msaouel, Juhee Lee, Peter F. Thall

Publication date: 29 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

clusteringadaptive randomizationdose findingBayesian phase I-II clinical trial designpatient prognostic subgroups

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Related Items (2)

Biomarker-based precision dose finding for immunotherapy combined with radiotherapy ⋮ BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint

Cites Work

• Continual reassessment and related dose-finding designs
• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
• Frailty-Based Competing Risks Model for Multivariate Survival Data
• A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups
• Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity

This page was built for publication: Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups